Replies to post #162886 on Biotech Values

[pcrutch]

Do you think ENTA is a compelling play at these levels? What's their royalty and payouts on the HCV deal with ABBV?

[DewDiligence]

ABBV/ENTA—The multi-genotypic 2-DAA regimen of ENTA’s ABT-493 (PI) + ABBV’s in-house ABT-530 (NS5A) will enter phase-2 in 2014. (Source: ABBV’s CC today.)

Note: ENTA receives a higher royalty on this 2-DAA regimen than on the 3-DAA combination currently in phase-3.